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The gene MTS1 encodes p16INK4, an inhibitor of cyclin-
dependent kinase 4, and is frequently deleted, mutated,
or silenced by promoter methylation in melanoma cells
and in the germline of familial melanoma patients.
Although MTS1 may thus be the candidate melanoma
suppressor gene that maps to chromosome 9p21, it is not
clear how dysfunction at that locus temporally relates to
melanoma progression. To further test its role in sporadic
melanoma, the expression of p16INK4-protein and -mRNA
was characterized in melanomas and melanocytic nevi by
immunocytochemistry and in situ reverse transcriptase-
polymerase chain reaction. Histologic tissue sections
were immunolabeled with anti-p16INK4 antibody for 108
melanocytic lesions, including common and atypical
nevi, in situ melanomas, primary invasive melanomas,
and metastatic tumors. A subset of the lesions was
analyzed for expression of p16INK4-mRNA, employing
forward and reverse intron-bridging primers for reverse
transcriptase-polymerase chain reaction amplification of
the transcript corresponding to exons 1 and 2 of MTS1.
Convergent evidence from deletional mapping of melan-oma tumor cells (Fountain et al, 1992) and geneticlinkage analyses of melanoma kindreds (Cannon-Albright et al, 1992) has assigned a melanoma susceptibil-ity locus (MLM) to chromosome 9p21. Positional
cloning of the smallest region commonly deleted homozygously in
melanoma cell lines later identified a gene, multiple tumor suppressor
1 (MTS1), as the candidate locus for MLM (Kamb et al, 1994a; Nobori
et al, 1994). The cDNA coding sequence of the expressed protein,
p16INK4, had previously been identified with two-hybrid screening by
investigators searching for natural inhibitors of the cyclin dependent
kinases, which are molecules that enable passage of cells through G1-S
cell cycle checkpoints (Serrano et al, 1993). Subsequently, observations
of segregating germline mutations in melanoma kindreds (Hussussian
et al, 1994; Kamb et al, 1994b) and of somatic mutations in tumor cell
lines of multiple histogenetic lineages (Smith-Sørensen and Hovig,
1996) have strongly supported the candidacy of MTS1 as a general
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Strong immunolabeling was detected in the melanocytes
of common nevi and of nevi with architectural disorder
and cytologic atypia. By digital image analysis, in con-
trast, labeling intensity decreased significantly and pro-
gressively in the melanocytes of in situ, invasive, and
metastatic melanomas. Results from the in situ reverse
transcriptase-polymerase chain reaction analysis were
confirmatory, showing a strong signal in the melanocytic
nevi but progressive signal attenuation with increasing
stage of melanoma. These data indicate correlation
between gradual loss of expression of the MTS1 locus
and progression of melanoma, further supporting an
emerging role for the gene in the malignant transforma-
tion of melanocytes. The failure to demonstrate reduced
expression in nevi suggests either that these lesions are
not an early stage in melanoma development, in contrast
to prevailing assumptions, or that loss of p16INK4 function
is not an initiating event in melanocyte transformation.
Key words: dysplastic nevi/melanoma/MTS1/nevi. J Invest
Dermatol 110:932–938, 1998
tumor suppressor locus for common cancers and more specifically for
familial and sporadic melanoma.
Although inactivation of the MTS1 locus in cancer cells fits well
conceptually with its candidate role as a tumor suppressor gene, given
the apparently critical inhibitory function of p16INK4 in cell cycle
regulation, the temporal relationship of mutational lesions in the gene
to the initiation and progression of melanoma has not been elucidated.
It is generally acknowledged that, in accordance with the theory of
step-wise transformation, melanomas may evolve from melanocytic
nevi as precursor lesions having undergone the first stage(s) in the
neoplastic process (Clark et al, 1984; Elder et al, 1989). Indeed, the
spatial coexistence of incident melanomas with remnants of melanocytic
nevi observed in histologic sections by numerous studies, tends to
support this assertion (Skender-Kalnenas et al, 1995), as do observations
of malignant degeneration in congenital nevi and the direct correlation
between total numbers of nevi and relative risk for melanoma in the
case-control literature (reviewed by Piepkorn, 1994). It is reasonable
to expect, therefore, that the genome of nevus cells will harbor
the molecular alterations necessary for the initiation of melanoma.
Accordingly, we postulated that, given the strong case for MTS1 as a
major locus contributing to the development of melanoma, abnormalit-
ies in expression of the gene at the mRNA or protein level will be
demonstrable in the cells of melanocytic nevi. The studies presented
herein represent a test of this specific hypothesis and of the more
general hypothesis that inactivation of MTS1 correlates with progression
of melanoma. Furthermore, in view of the suggestion that expression
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of p16INK4 and the retinoblastoma gene product may be inversely
correlated in some tumor systems (Otterson et al, 1994), the status of
RB1 expression was compared with that of p16INK4 in a subset of the
lesions. Our results extend those of Reed et al (1995) and Talve et al
(1997), who immunolabeled melanocytic lesions with antibodies against
p16INK4. In qualitative analyses, Reed et al (1995) observed decreased
labeling in invasive and metastatic melanomas, but uniform labeling in
melanocytic nevi and in situ melanomas, suggesting that loss of p16INK4
expression may not be an initiating event in transformation. Talve et al
(1997) confirmed both the uniform labeling of nevus cells and the loss
of expression with melanoma progression, but they observed decreased
expression in melanoma in situ. Neither study specifically evaluated
atypical (dysplastic) nevi. As reported herein, our observations support
the findings of Talve et al (1997) that p16INK4 immunostaining is
reduced in some melanomas in situ, which is consistent with the locus
being an early target in melanoma initiation. The original aspects of our
report include: quantitation of p16INK4 immunostains of melanocytic
tumors by digital image analysis; the observation of normal levels of
p16INK4 immunolabeling in atypical nevi, which is notable because
such lesions are purported to be melanoma precursor lesions; the lack
of an apparent inverse correlation between p16INK4 and RB1 expression
in melanomas; and the finding that expression levels of p16INK4 mRNA
by in situ reverse transcriptase polymerase chain reaction (RT-PCR)
correlate with reductions in p16INK4 immunolabeling during melanoma
progression.
MATERIALS AND METHODS
Cell culture Primary keratinocyte and melanocyte cultures were established
from human neonatal foreskins (Fligiel et al, 1992; Piepkorn et al, 1994) and
grown in complete keratinocyte growth medium (cKGM; Clonetics, San Diego,
CA), or complete melanocyte growth medium (cMGM; Clonetics), respectively.
The cells were used at the second to fourth passage levels. Human melanoma
cell lines HTB 66, HTB 70, and HTB 71, and a human breast cancer cell line,
MCF7, were obtained from the American Type Culture Collection (Rockville,
MD) and grown as monolayered cultures in Dulbecco’s minimum essential
medium (BioWhittaker, Walkersville, MD), containing 10% fetal bovine serum
(Intergen, Purchase, NY). Two days prior to the immunolocalization experi-
ments, cells of each cell type were subcultured into LabTek chamber slides
(Nunc, Naperville, IL) at 1–2 3 104 cells per cm2.
Tissue samples Five micrometer recuts were prepared from formalin-fixed,
paraffin-embedded tissues retrieved from the pathology files of the University
of Washington Medical Center. The specimens consisted of 108 melanocytic
lesions, including common and atypical nevi, in situ melanomas, primary invasive
melanomas, and metastatic tumors. The original diagnoses were confirmed by
review of the hematoxylin and eosin stained sections using standard diagnostic
criteria for each lesion type as applied by one of us (MP). The diagnoses of the
metastatic lesions were corroborated by review of the routine histology and
immunoperoxidase studies with markers for S100 protein and/or HMB-45.
Western immunoblotting The specificities of the anti-p16INK4 mouse
monoclonal antibody, G175–405, and the anti-retinoblastoma protein (RB1)
monoclonal antibody, G3–245 (both purchased from PharMingen, San Diego,
CA), were established by western immunoblotting of cell extracts from human
neonatal keratinocyte and melanocyte cultures, established melanoma cell lines,
and a breast cancer cell line (MCF 7). Cell layers in exponential growth were
washed twice with chilled phosphate-buffered saline and scraped into 300 µl
of cold lysis buffer (50 mM Tris HCl, 0.25 M NaCl, 0.1% Triton X-100,
1.0 mM ethylenediaminetetraacetic acid, 50 mM NaF, 1.0 mM dithiothreitol,
0.1 mM Na3VO4) with 0.1 mM phenylmethylsulfonyl fluoride, 1 µg leupeptin
per ml, 10 µg soybean trypsin inhibitor per ml, 10 µg N-tosyl-L-phenylalanine
chloromethyl ketone per ml, 10 µg Na-p-tosyl-L-lysine chloromethyl ketone
per ml, and 1 µg aprotinin per ml (Tam et al, 1994). Following incubation on
ice for 30 min, the cells were pooled and homogenized, and the homogenates
were centrifuged for 5 min at 300 3 g at 4°C. The protein concentrations in
the supernatants were measured with the Bio-Rad protein assay (Bio-Rad
Laboratories, Richmond, CA), and the supernatants were concentrated into
sample buffer. Twenty-five to 50 µg of total protein from each cell extract
were resolved electrophoretically by nonreducing sodium dodecyl sulfate-
polyacrylamide gel electrophoresis, along with molecular-weight markers
(Amersham, Arlington Heights, IL; Gibco BRL, Gaithersburg, MD; and Novex,
San Diego, CA) using 12% and 7.5% acrylamide gels. The gels were transferred
for 1 h at 100 V to nitrocellulose sheets (BioRad), which were blocked with
Tris-saline (50 mM Tris base, 0.15 M NaCl, pH 7.4) containing 0.25% gelatin/
Figure 1. Specificity of the G175–405 anti-p16INK4 monoclonal antibody
established by western immunoblotting of cell extracts from
keratinocytes and melanocytes, melanoma lines, and the MCF 7
mammary carcinoma line. The keratinocyte, melanocyte, and HTB 66
extracts have been resolved in lanes 4, 6, and 8 and the p16INK4 negative cell
lines (HTB 70, HTB 71, and MCF 7) in lanes 2, 3, and 7, respectively.
Molecular weight markers are represented in the first and fifth lane. In addition
to p16INK4, G175–405 also detected a faint, uncharacterized band at µ27 kDa,
which others have previously observed with this and other anti-p16INK4
antibodies. The molecular weight of the standard marker is indicated in the left
margin. Detection was by enhanced chemiluminescence.
0.05% NP-40 (Sigma, St. Louis, MO)/5 mM ethylenediaminetetraacetic acid
for 1 h at room temperature and incubated with a 1:250 dilution of the primary
anti-p16INK4 antibody or anti-RB1 antibody stock solution (0.5 mg per ml)
overnight at 4°C. The blots were washed with buffer three times and incubated
with 1:1000 secondary, horse anti-mouse antibody conjugated to horseradish
peroxidase (Vector Laboratories, Burlingame, CA) for 60 min at room temper-
ature. Following a wash with 0.25% gelatin/0.05% NP-40/0.4% sarcosyl in
Tris-saline, immunolocalization was by enhanced chemiluminescence according
to the manufacturer (ECL, Amersham) with 3 to 40 s exposure times (see Fig 1).
Immunostaining In preliminary analyses, the G175–405 and G3–245 anti-
bodies were determined to specifically detect p16INK4 and RB1, respectively,
in frozen and formalin-fixed tissue samples. Antibody localization was by avidin-
biotin peroxidase staining of histologic sections from benign and malignant
melanocytic lesions and by fluorescein immunofluorescence of cultured ker-
atinocytes, melanocytes, melanoma cells, and breast cancer cells grown on slide
chambers. For immunohistochemistry, 5 µm paraffin sections of formalin-fixed
tissue were deparaffinized and rehydrated through a graded series of ethanol.
After blocking of endogenous peroxidase activity with 0.3% hydrogen peroxide,
the sections for RB1 immunolabeling were processed in a 750 Watt microwave
oven at maximum power, twice, for 4 min, to enhance antigen detection.
Sections were blocked with Tris-saline, pH 7.5, containing serum and 0.1%
bovine serum albumin, and incubated with either a 1:100 or a 1:150 dilution
of the primary anti-p16INK4 or anti-RB1 antibody, or buffer or preimmune
mouse serum as negative controls, overnight at 4°C. Following three buffer
washes of the sections, the secondary biotinylated horse anti-mouse antibody
conjugated to biotin (1:200, Vector Laboratories) and peroxidase-labeled strepta-
vidin (1:50, Vector Laboratories) were sequentially applied for 30 min at room
temperature, and reaction product was visualized with hydrogen peroxide and
39-amino 99-ethylcarbazole (AEC, Sigma) as chromogenic substrate.
For subcellular localization of immunofluorescence labeled product, the cell
layers on the chamber slides were rinsed in phosphate-buffered saline, fixed in
methanol at –20°C for 2 min, rinsed, blocked with serum, and reacted with
the anti-p16INK4 antibody (1:100) or the anti-RB1 antibody (1:150) overnight
at 4°C. For anti-p16 labeling, the secondary antibody (horse anti-mouse
conjugated to fluoroscein isothiocyanate, Vector Laboratories), diluted at 1:100,
was applied for 30 min. The anti-RB1 exposed slides were sequentially
incubated with the secondary biotinylated horse anti-mouse antibody (1:200)
and with Texas Red-conjugated streptavidin (1:1000, Vector Laboratories). The
slide chambers were washed, mounted with Vectashield (Vector Laboratories),
and viewed using a Zeiss Universal microscope equipped with epi-illumination
or with a Bio-Rad MRC-600 laser scanning confocal microscope.
Image analysis Immunoperoxidase labeling intensities were quantitated with
an image analysis system based on Optimas 4.0 image analysis software (Optimas,
Bothell, WA), using a World Video CCD camera connected to a Leitz Laborlux
D microscope (Leitz, Wetzlar, Germany) with a stabilized power supply and a
VisionPlus-AT CFG frame grabber (Imaging Technologies, Woburn, MA).
Except as noted, a random sampling strategy was followed. After properly
decalibrating the system (Hugo et al, 1996), representative fields were captured
(320 objective) and corrected for uneven illumination. Cells underlying
computer-generated random coordinates in each field were manually outlined
and the average inverse log of the inverse gray value (which is proportional to
the amount of light absorbing material in the light path) was computed for all
pixels in each cell. Twenty cells were analyzed in each of 10 fields for each
lesion. Data were exported to Excel (Microsoft, Redmond, WA) for analysis
and graphical display. For in situ melanomas, slides were analyzed by manually
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Table I. Forward and reverse primers for p16INK4 amplificationa
Primers Position Annealing temperature Product size (bp)
Sense 59TACGGTCGGAGGCCGATCCAGGTC 170–193 57°C 336
Anti-sense 59GGGGATGTCTGAGGGACCTTCCGC 482–505
aTo reduce the generation of PCR products from genomic DNA, intron bridging primers were designed.
Figure 2. Immunostained p16INK4 (A, C)
and RB1 (B, D) localized by scanning laser
confocal microscopy. (A) HTB 66 melanoma
cells demonstrated a diffuse cytoplasmic staining
pattern with random perinuclear activity and
focal granular nuclear labeling for p16INK4. (B)
Granular nuclear staining for RB1 was observed
in HTB 66. (C) Immunofluorescence staining
of the p16INK4-negative cell line HTB 70
showed only minimal nonspecific background
fluorescence and no detectable protein. (D)
HTB 70, as well as all the other tested cell
types (not shown), displayed granular nuclear
staining for RB1.
Table II. p16INK4 is differentially expressed in benign and
malignant melanocytic lesions
Expression Melanocytic Melanoma 1° Invasive Metastatic
levela nevi in situ melanoma melanoma
0 – – – 1 (3%)
0–11 – – – 1 (3%)
11 1 (2%) – 3 (18%) 4 (12%)
1–21 1 (2%) – – –
21 5 (10%) 1 (14%) 3 (18%) 7 (21%)
2–31 – 1 (14%) 1 (6%) 4 (12%)
31 44 (86%) 5 (72%) 10 (59%) 16 (49%)
Number 51 7 17 33
of lesions
a0, nonreactive; 11, less than one-third of melanocytic cells showing uniform labeling;
21, one- to two-thirds showing uniform labeling; 31, at least two-thirds showing
uniform labeling.
selecting representative neoplastic melanocytes because the pagetoid distribution
of these cells within the epidermal keratinocytes did not lend itself to random
sampling from computer generated coordinates. For comparison, slides of other
lesions were also analyzed using manual sampling. Average cell labeling was
similar for the two sampling strategies but the randomly selected cells generally
exhibited greater variability of staining between cells (not shown). Variability
in staining was reduced by batch processing of those lesions for which labeling
intensities were compared.
In situ RT-PCR A four-step protocol described by Nuovo (1994) was used
to localize p16INK4-specific mRNA sequences within melanocytic lesions. Five
micrometer thick paraffin-sections of formalin-fixed tissue were transferred to
silane-coated slides, dewaxed, and protease digested to facilitate reagent penetra-
tion into the cells. The sections were incubated with pepsin (Sigma) at 2 mg
per ml for varying incubations (15–90 min), as adjusted for the estimated lengths
of time the tissues had been fixed in formalin. The RT and PCR steps were
performed in a GeneAmp In Situ PCR System 1000 (Perkin-Elmer, Foster
City, CA). After digestion with 10 U per tissue section of RNase-free DNase
(Boehringer Mannheim, Indianapolis, IN), to block amplification of genomic
DNA, the mRNA was reverse-transcribed to generate cDNA templates by
SuperScript S2 Reverse Transcriptase (BRL, Gaithersburg, MD), according to
the manufacturer’s specifications. For PCR amplification of the cDNA and
direct labeling of the amplified product, the following mixture was used:
2.5 mM MgCl2, 200 µM cocktail of dNTP, 10 µM digoxigenin-11–29-
deoxyuridine-59-triphosphate (Boehringer Mannheim), 0.8 µM forward and
reverse primers (see Table I), 0.08% bovine serum albumin (Sigma), and 2.5 U
Taq DNA Polymerase (BRL). Synchronized ‘‘hot start’’ PCR was achieved
using the temperature-sensitive Taq-blocking monoclonal antibody supplied by
Clontech (Palo Alto, CA) (Kellog et al, 1994; Martı´nez et al, 1995). A 25 µl
aliquot of solution was applied to each section and 20 thermal cycles proved
adequate to obtain crisp staining. Detection of the digoxigenin-labeled product
utilized a kit from Boehringer Mannheim, which employed an anti-digoxigenin
alkaline phosphatase-conjugated antibody, followed by exposure to nitroblue
tetrazolium chloride and 5-bromo-chloro-3-indolyl-phosphate. The dark-
purple reaction product was visualized by bright-field microscopy.
Negative (DNase-digestion, no reverse transcriptase) and positive controls
(no DNase-digestion) were performed on the same glass slide with each test.
Before the final in situ RT-PCR analyses, all parameters for the PCR reaction,
including MgCl2 concentration, pH, and annealing temperature, had been
optimized by standard solution phase PCR.
RESULTS
Specificities of the anti-p16INK4, G175–405, and the anti-
RB1, G3–245, monoclonal antibodies established by western
immunoblotting The specificities of the p16INK4 and RB1
antibodies were evaluated by western immunoblotting of cell
extracts from human neonatal keratinocyte and melanocyte cultures,
established melanoma cell lines, and a breast cancer cell line (MCF
7). A full-length recombinant bacterially produced GST-p16INK4
fusion protein was used as immunogen for preparation of the anti-
p16INK4 antibody (Serrano et al, 1993). A major band migrating
with an apparent mass of µ16 kDa was detected from keratinocyte,
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Figure 3. Patterns of p16INK4 expression in
histologic sections of benign and
malignant melanocytic lesions.
Immunolabeling for p16INK4 revealed intense,
and somewhat uniform staining of nevus cell
nests at all dermal levels in (A) an intradermal
nevus and (B) nevus cells arrayed along the
basal epidermal layer in a compound nevus
with architectural disorder and cytologic atypia
(dysplastic nevus). (C) Less intense p16INK4
expression is shown in a lesion of melanoma in
situ. (D) Labeling attenuated and was
nonuniform in a metastatic deposit of melanoma
within a lymph node.
Table III. RB1 status is independent of p16INK4 expression in
melanocytic lesions
Expression level RB1 , 30%a RB1 ù 30%a Total
p16INK4 0–21 4 (14%) 7 (25%) 11
p16INK4 .21 2 (7%) 15 (54%) 17
Total 6 22 28b
aProportion of cells with nuclear labeling.
bn 5 28 (four nevi, three atypical nevi, three melanomas in situ, seven primary invasive
melanomas, 11 metastatic melanomas).
melanocyte, and HTB 66 cell extracts (Fig 1). The absence of
significant bands from p16INK4-negative cell lines HTB 70, HTB
71, and MCF 7 indicates no nonspecific cross-reactivity with other
cellular proteins (Fig 1). G3–245, the anti-RB1 antibody, recognizes
an epitope corresponding to amino acid residues 300–380 of the
human retinoblastoma protein (pp110–114 RB1) (De Caprio et al,
1988). Major bands at µ110–116 kDa (Riley et al, 1994) were
strongly labeled in HTB 70, HTB 71, and MCF 7 extracts and
more weakly labeled in extracts of melanocytes, keratinocytes, and
HTB 66 cells (not shown). Labeling intensities were greater in the
p16INK4-negative cell lines (HTB 70, HTB 71, and MCF 7),
suggesting that RB1 is overexpressed as a consequence of upregulated
cyclin D-CDK4 activity.
Subcellular localization of immunolabeled p16INK4 and RB1
imaged by confocal microscopy For localization of p16INK4
and RB1 proteins by immunofluorescence, cultures of human
neonatal keratinocytes and melanocytes, established melanoma cell
lines, and a breast cancer cell line (MCF 7) were immunolabeled
with anti-p16INK4 or anti-RB1 antibody and detected with fluoroscein
isothiocyanate- or Texas Red-conjugated secondary antibodies.
Subcellular localization was imaged by scanning laser confocal
microscopy, and the results for the HTB 66 and HTB 70 cell lines
are illustrated in Fig 2. Immunolabeled p16INK4 displayed diffusely
granular cytoplasmic fluorescence, with random perinuclear and focal
granular nuclear staining, in melanocytes, keratinocytes, and the
HTB 66 melanoma cell line (Fig 2A). In contrast, there was no
detectable immunolabeling of the p16INK4-negative cell lines MCF
7, HTB 71, and HTB 70 (Fig 2C). Reed et al (1995) also reported
combined cytoplasmic and nuclear staining by immunoperoxidase
labeling of melanocytic cells with a polyclonal anti-p16INK4 antibody.
Immunolabeling with anti-RB1 demonstrated granular nuclear, but
minimal cytoplasmic, staining for all tested cell types, as illustrated
in Fig 2(B, D) for HTB 66 and HTB 70, respectively.
Immunolabeling patterns for p16INK4 and RB1 in melanocytic
lesions are distinct Immunoperoxidase staining for p16INK4 and
RB1 was performed on histologic sections from benign and
malignant melanocytic lesions. Keratinocytes, which were found in
these studies to strongly express p16INK4, served as positive internal
controls for those lesions present within skin. The slides were
reviewed independently by two observers; the semiquantitative visual
scores are summarized in Table II. Uniform labeling in at least
two-thirds of melanocytic cells was detected in 86% of common
and atypical melanocytic nevi (Fig 3A, B). Labeling at this
proportion of the cell populations decreased to 72% for melanomas
in situ (Fig 3C) and to 59% for primary invasive melanomas,
whereas only 49% of metastatic tumors expressed p16INK4 at this
level (Fig 3D). p16INK4 labeling thus attenuated with advancement
in tumor stage, as referenced to the consistent staining of keratinocytes
as the internal control. Because it has been suggested that p16INK4
and RB1 expression may be inversely correlated in some tumor
systems (Otterson et al, 1994), and because nuclear expression of
RB1 has been reported to be higher in melanomas than in nevi
(Saenz-Santamaria et al, 1995), immunohistochemistry for RB1 was
also performed in about one-third of the melanocytic lesions that
had been immunolabeled for p16INK4 (Table III). No inverse
correlation between the RB1 status and p16INK4 expression was
observed in this series. Strong labeling for p16INK4 and RB1 was
detected in 54% of the melanocytic lesions, and only 7% strongly
expressed p16INK4 when RB1 staining was minimal to negative. A
similar absence of inverse correlation between the expression levels
of p16INK4 and RB1 by immunolabeling has been reported in
nonmelanoma malignancies (Geradts et al, 1995).
Intensity of p16INK4 immunolabeling quantitatively attenuates
with melanoma progression Histologic slides immunostained for
p16INK4 were quantitated for labeling intensity with the Optimas
image analysis system (Materials and Methods). The results are
presented in Fig 4. In seven cases of melanomas with coexisting
melanocytic nevi, the nevus cells strongly expressed p16INK4, whereas
adjacent melanoma cells consistently displayed reduced staining
intensity, and the keratinocytes expressed p16INK4 at an intermediate
level (Fig 4A). Quantitative comparisons of the levels of p16INK4
936 KELLER-MELCHIOR ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
Figure 4. p16INK4 labeling intensity correlates with disease progression in
melanoma. (A) p16INK4 immunostaining intensities in epidermal keratinocytes,
nevus cells, and melanoma cells were quantitated in histologic sections of seven
different melanomas with coexisting nevi. For this analysis, the cells were
manually selected. Data are shown as means 6 SEM for 200 cells. The labeling
for p16INK4 was consistently greater in nevus cells than in melanoma cells, and
keratinocytes expressed p16INK4 at an intermediate level. The differences
between the means for the nevus and melanoma cells, combined for the seven
pairs of data, are significant at p , 10–4 by Student’s t test. (B) Quantitation of
immunostaining intensities in common and atypical nevi, melanomas in situ,
primary invasive melanomas, and metastatic melanomas indicated strong
expression of p16INK4 in nevus cells and progressive decrease in label intensity
with advancement in melanoma stage. Each bar represents the mean with 95%
confidence interval of the labeling intensity of 200 cells selected by computer
randomization from each lesion (see Materials and Methods). Differences between
the means for the common and atypical nevi are not statistically significant in
this series, whereas the mean labeling intensities for melanoma in situ, invasive
melanoma, and metastatic melanoma are significantly decreased compared with
the mean for common nevi at p , 10–4 by the Mann–Whitney U test. AN,
atypical nevi; MIS, melanoma in situ; IM, invasive melanoma; MM, metastatic
melanoma. Numbers of lesions are given in parentheses.
Table IV. p16INK4 mRNA expression in melanocytic
lesions correlates with p16INK4 immunolabeling
Protein expression mRNA expression
levela levela
Lesion type Number 11 21 31 11 21 31
Nevus 23 0 1 22 0 5 18
Atypical nevus 15 0 2 13 0 4 11
Melanoma:
in situ 4 0 1 3 0 2 2
Invasive 6 0 1 5 0 4 2
Metastatic 13 4 4 5 3 4 6
a11, less than one-third of melanocytic cells with uniform labeling; 21, one- to two-
thirds with uniform labeling; 31, at least two-thirds with uniform labeling.
expression between common nevi, atypical nevi, melanomas in situ,
primary invasive melanomas, and metastatic tumors indicated that
p16INK4 labeling intensity was strong in both the common and the
atypical nevi, but attenuated progressively with advancement in
tumor stage from in situ to metastatic melanoma (Fig 4B).
Expression levels of p16INK4 mRNA by in situ RT-PCR
correlate with immunolabeling of p16INK4 in melanocytic
lesions Results from p16INK4 immunolabeling were correlated
with expression of p16INK4 mRNA by in situ RT-PCR in
approximately two-thirds of the melanocytic lesions (Table IV). As
with p16INK4 immunolabeling, uniform expression of p16INK4-
mRNA in a majority of the lesional melanocytic cells was detected
in 18 of 23 (78%) common nevi that were examined, whereas
expression at this level was observed in only six of 13 (46%)
metastatic melanomas. The same lesions that showed low levels of
protein labeling also expressed low amounts of p16INK4 mRNA.
Figure 5 illustrates the correlation between p16INK4 immunolabeling
and in situ RT-PCR in a case of superficial spreading melanoma.
Overall, therefore, expression of p16INK4-protein and -mRNA in
the 61 melanocytic lesions was concordant.
DISCUSSION
With these studies we have further evaluated the chromosome 9p21
locus, MTS1, as a candidate melanoma suppressor gene in a series
of melanocytic lesions ranging from common nevi to metastatic
melanoma. Immunolabeling of the expressed product, p16INK4, was
correlated with analysis for p16INK4-mRNA by in situ RT-
PCR with intron bridging primers and was compared with the
immunolabeling status of RB1 in a representative subset of the
lesions. The specificity of the p16INK4 monoclonal antibody used
for these purposes was corroborated by western immunoblotting of
normal and transformed cell lines, including cells that do not express
p16INK4 (Fig 1). Imaging of immunolabeled p16INK4 by scanning
laser confocal microscopy indicated that the protein is distributed
to both the cytoplasms and the nuclei of normal and transformed
melanocytes, in agreement with previous studies (Reed et al, 1995;
Talve et al, 1997), whereas RB1 was generally restricted to the
nuclei (Fig 2). No inverse correlation was apparent between the
expression status of RB1 and p16INK4 in these melanocytic lesions,
contrary to expectations. Moreover, expression levels of p16INK4-
protein and -mRNA in the nevomelanocytes of both common and
atypical (dysplastic) nevi were not appreciably reduced. The
transformed melanocytes of in situ, invasive, and metastatic melanomas,
however, expressed p16INK4 at significantly reduced levels by
quantitative immunolabeling (Fig 4), and an inverse correlation
between p16INK4-protein and -mRNA levels and stage of the disease
was observed, suggesting a role in the progression of melanoma.
Current understanding of neoplastic transformation invokes a step-
wise pathway of progression to the fully malignant phenotype in
tumor systems. This paradigm has been best characterized from
studies of colon carcinoma cells (Powell et al, 1992), but it may be
generally applicable to many tumor systems, including that of
melanoma (Elder et al, 1989). Under the general model of melanoma
progression, certain morphologic variants of melanocytic nevi have
been incorporated as a first stage in carcinogenesis (Clark et al,
1984; Elder et al, 1989). It is reasonable, therefore, to evaluate
these putative precursor lesions for molecular alterations in the
search for the events initiating transformation to melanoma.
The familial melanoma locus, MTS1, is a plausible target for a
genetic lesion that initiates transformation. Data acquired from the
genetic linkage of MTS1 markers at chromosome 9p21 to familial
melanoma (Cannon-Albright et al, 1992) and from deletional
mapping of melanoma tumors, which has shown chromosome 9p21
to be the most common genomic target for loss of heterozygosity
and homozygous deletions in some analyses (Fountain et al, 1992),
are compatible with a role in tumor initiation. The alternative
hypothesis of a more distal event in progression is counterintuitive,
unless another covert initiating mutation depends on coordinate,
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Figure 5. Expression of p16INK4 mRNA by
in situ RT-PCR correlates with p16INK4
immunolabeling in a melanoma. (A) For
this Clark level II (Breslow 0.7 mm) lesion,
p16INK4 immunolabeling displays uniform
staining of the melanoma cells. (B) In situ RT-
PCR for p16INK4 mRNA reveals dark purple
staining of the amplified product in the
cytoplasm of the cells, correlating with the
p16INK4 immunolabeling. The corresponding
positive control (C) omitting the DNase
digestion step and the negative control without
reverse transcription (D) exhibited intense
nuclear and no staining, respectively. The scale
in (A)–(C) is as depicted in (D).
distal inactivation of MTS1 for clinically overt disease in the families
that were used for genetic linkage.
Our data are consistent with an important role for p16INK4
inactivation during melanoma progression, regardless of the actual
chronology. A perceptible decrease in the expression level of p16INK4-
protein and -mRNA was observed in melanomas, commencing with
the first clearly recognizable stage of the disease, that of the in situ
lesions (Fig 4B). Moreover, there was attenuation in the expression
level with advancing stage of melanoma. Whereas these results do
not of course discriminate between an initiating or more distal
event, decreased expression of MTS1 during tumor progression is
obviously not an all-or-none event, but rather a graded process.
This suggests a stoichiometric mechanism for carcinogenesis, such
as one where a molar deficiency of p16INK4 has the net effect of
upregulating the activation of CDK4 by cyclin D through loss of
competitive inhibition. There would then be more inactivation by
phosphorylation of RB1, the target substrate of CDK4, forcing the
equilibrium in the direction of unregulated cell growth, thereby
fostering malignant transformation. As suggested by our data, the
regulatory effects of p16INK4 at the late G1 cell cycle checkpoint
may be progressively lost as the expression of the gene product
attenuates with advancing stage of melanoma. It must be noted,
however, that p16INK4-protein and -mRNA levels were normal in
some fully evolved melanomas in this series, although abnormal
p16INK4 function due to intragenic point mutations could not be
ruled out. A role for other parallel molecular pathways of oncogenesis
is suggested in these cases.
In the report of Reed et al (1995), qualitatively uniform labeling
with a polyclonal antibody was observed in 100% of common and
atypical nevi and in situ melanomas, but there was reduced labeling
of primary invasive and metastatic tumors. The results of Talve et al
(1997) using a monoclonal antibody were similar, although some
melanomas in situ failed to immunolabel for p16INK4. Taken together
with our corroborating data from quantitative immunolabeling with
a monoclonal antibody and from in situ RT-PCR with specific
primers for p16INK4-mRNA, it can be reasonably concluded that
expression of p16INK4 is progressively lost with advancement in
tumor stage in many cases of melanoma. Moreover, this study and
those of both Reed et al (1995) and Talve et al (1997) are
concordant for apparently normal expression levels in nevi. In
support of the results of Talve et al (1997), however, we observed
that mean expression levels are significantly decreased in melanomas
in situ. This difference in the results could be methodologic in
nature or could reflect variations in the composition of the samples.
Neither of the other studies specifically evaluated atypical nevi,
which as described herein express normal levels of p16INK4 protein
and mRNA. Whereas Reed et al (1995) concluded from their data
with nevi and melanomas in situ that inactivation of MTS1 is not
an initiating event, our observations and those of Talve et al (1997)
would be consistent with a more proximal stage for MTS1 inactivation
if melanocytic nevi are set aside as formal precursor lesions.
Whereas the precise nature of melanocytic nevi and their biologic
function, if any, remain largely unknown, a precursor relationship
with melanoma has been widely accepted from several lines of
evidence (Skender-Kalnenas et al, 1995). If the validity of this
conventional model is assumed, such that nevi constitute a proximate
morphologic stage in melanoma carcinogenesis (Clark et al, 1984;
Elder et al, 1989), then our data showing apparently nominal levels
of p16INK4-protein and -mRNA in common and atypical nevi
would indicate that loss of its expression is not an initiating event.
The alternative interpretation is that nevi may not be a first step
in malignant transformation, which could accommodate an early,
rate limiting role for MTS1 in the process. There in fact exist
empiric observations inconsistent with the position of melanocytic
nevi as proximate precursor lesions to melanoma. Among these are
the generally low expression levels of proliferation markers in nevus
cells (Saenz-Santamaria et al, 1994), the upregulation of apoptocytic
factors in nevi (Kanik et al, 1995), and the difficulty in culturing
the cells. Such observations, taken together with those reported
here, invoke the question of the pathophysiologic role of nevi.
One reasonable view is that the spatial association of nevi with
melanomas reflects pleiotropic, and divergent, processes sharing a
common causation, rather than sequential phases in a continuous,
linear progression. This hypothesis, which would account for many
of the empiric data, suggests a biologic function for nevi as an
adaptive or protective response to melanocytic injury.
The studies were supported in part by U.S. Public Health Service grant no. AR
21557 from the National Institutes of Health, Department of Health and Human
Services. The authors gratefully acknowledge the excellent technical assistance of Ms.
Thao Pham. Regine Keller-Melchior was supported by a grant from the Deutsche
Krebshilfe, Bonn, Germany.
938 KELLER-MELCHIOR ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
REFERENCES
Cannon-Albright LA, Goldgar DE, Meyer LJ, et al: Assignment of a locus for familial
melanoma, MLM, to chromosome 9p13-p22. Science 258:1148–1151, 1992
Clark WH Jr, Elder DE, Guerry DIV, Epstein MN, Greene MH, Van Horn M: A study
of tumor progression: the precursor lesions of superficial spreading and nodular
melanoma. Human Pathol 15:1147–1165, 1984
De Caprio JA, Ludlow JW, Figge J, et al: SV40 large tumor antigen forms a specific
complex with the product of the retinoblastoma susceptibility gene. Cell 54:275–
283, 1988
Elder DE, Rodeck U, Thurin J, Cardillo F, Clark WH, Stewart R, Herlyn M: Antigenic
profile of tumor progression stages in human melanocyte nevi and melanomas.
Cancer Res 49:5091–5096, 1989
Fligiel SEG, Inman DR, Talwar HS, Fisher GJ, Voorhees JJ, Varani J: Modulation of
growth in normal and malignant melanocytic cells by all-trans retinoic acid. J Cutan
Pathol 19:27–33, 1992
Fountain JW, Karayiorgou M, Ernstoff MS, et al: Homozygous deletions within human
chromosome band 9p21 in melanoma. Proc Natl Acad Sci USA 89:10557–10561, 1992
Geradts J, Kratzke RA, Niehans GA, Lincoln CE: Immunohistochemical detection of the
cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/
MTS1) product p16INK4A in archival human solid tumors: Correlation with
retinoblastoma protein expression. Cancer Res 55:6006–6011, 1995
Hugo C, Hugo C, Pichler R, et al: Radixin and moesin, cytoskeleton linking proteins,
are involved in glomerular cell migration and remodelling in experimental glomerular
disease. J Clin Invest 97:2499–2508, 1996
Hussussian CJ, Struewing JP, Goldstein AM, et al: Germline p16 mutations in familial
melanoma. Nature Genet 8:15–21, 1994
Kamb A, Gruis NA, Weaver-Feldhaus J, et al: A cell cycle regulator potentially involved
in genesis of many tumor types. Science 264:436–440, 1994a
Kamb A, Shattuck-Eidens D, Eeles R, et al: Analysis of the p16 gene (CDKN2) as a
candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet 8:22–
26, 1994b
Kanik AB, Yaar M, Bhawan J: p75 nerve growth factor receptor staining helps identify
spindle cell melanomas. J Cutan Pathol 22:68 (abstract), 1995
Kellog DE, Rybalkin I, Chen S, Mukhamedova N, Vlasik T, Siebert PD, Chenchik A:
Taq-Start antibody: ‘‘hot start’’ PCR facilitated by a neutralizing monoclonal antibody
directed against Taq DNA polymerase. BioTechniques 16:1134–1137, 1994
Martı´nez A, Miller M-J, Quinn K, Unsworth EJ, Ebina M, Cuttita F: Non-radioactive
localization of nuclear acids by direct in situ PCR and in situ RT-PCR in paraffin-
embedded sections. J Histochem Cytochem 43:739–747, 1995
Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA: Deletions of the cyclin-
dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753–
756, 1994
Nuovo GF: PCR In Situ Hybridization: Protocols and Applications, 2nd edn. Raven Press,
New York, 1994
Otterson GA, Kratzke RA, Coxon A, Kim YW, Kaye FJ: Absence of p16INK4 protein is
restricted to the subset of lung cancer cell lines that retains wildtype RB. Oncogene
9:3375–3378, 1994
Piepkorn MW: Genetic basis of susceptibility to melanoma. J Am Acad Dermatol 31:1022–
1039, 1994
Piepkorn M, Lo C, Plowman G: Amphiregulin-dependent proliferation of cultured human
keratinocytes: Autocrine growth, the effects of exogenous recombinant cytokine,
and apparent requirement for heparin-like glycosaminoglycans. J Cell Physiol 159:114–
120, 1994
Powell SM, Zilz N, Beazer-Barclay Y, et al: APC mutations occur early during colorectal
tumorigenesis. Nature 359:235–237, 1992
Reed JA, Loganzo F Jr, Shea CR, et al: Loss of expression of the p16/cyclin-dependent
kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with
invasive stage of tumor progression. Cancer Res 55:2713–2718, 1995
Riley DJ, Lee EY-HP, Lee W-H: The retinoblastoma protein: More than a tumor
suppressor. Annu Rev Cell Biol 10:1–29, 1994
Saenz-Santamaria MC, Reed JA, McNutt NS, Shea CR: Immunohistochemical expression
of BCL-2 in melanomas and intradermal nevi. J Cutan Pathol 21:393–397, 1994
Saenz-Santamaria MC, McNutt NS, Shea CR: Immunohistochemical expression of
retinoblastoma protein in cutaneous melanomas. Br J Dermatol 133:890–895, 1995
Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing
specific inhibition of cyclin D/CDK4. Nature 366:704–707, 1993
Skender-Kalnenas TM, English DR, Heenan PJ: Benign melanocytic lesions: Risk markers
or precursors of cutaneous melanoma? J Am Acad Dermatol 33:1000–1007, 1995
Smith-Sørensen B, Hovig E: CDKN2A (p16INK4A) somatic and germline mutations.
Human Mutation 7:294–303, 1996
Talve L, Sauroja I, Collan Y, Punnonen K, Erfors T: Loss of expression of the
p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor
cell proliferation and invasive stage. In J Cancer 74:255–259, 1997
Tam SW, Shay JW, Pagano M: Differential expression and cell cycle regulation of the
cyclin-dependent kinase 4 inhibitor p16INK4. Cancer Res 54:5816–5820, 1994
